Virbac points to research showing that MCTs are the most common form of skin cancer in dogs, accounting for up to 21% of skin cancer cases1.
This, says the company, means that understanding the challenges surrounding mast cell tumour diagnosis, work up (including the various prognostic panels) and treatment selection for mast cell tumour cases is vital.
The session, entitled ‘Fundamentals of Mast Cell Tumour Management’, will conclude with a review of Stelfonta, walking through cases and how to get the best results.
Dr Neil Mottram MRCVS, Technical Product Manager at Virbac said: "We know that vets are facing webinar fatigue.
"We therefore hope that this brand new style of online learning on one of the most common canine cancers will be more engaging, whilst still delivering high quality CPD."
To register for the live event, visit: https://tinyurl.com/mct-masterclass
For more information, speak to your Virbac Territory Manager, or visit vet-uk.virbac.com/stelfonta
Reference
BVA president-elect John Blackwell has found himself on the front page of The Times today, and interviewed on Radio 4's Today programme, with a call to end the practice of slitting animal's throats and allowing them to bleed to death in order to produce kosher and halal meat.
According to the newspaper, 600,000 animals are killed this way every week in the UK.
Mr Blackwell is urging Jews and Muslims to allow meat-producing animals to be stunned before they are killed.
Speaking to The Times, Mr Blackwell said: "As veterinary surgeons, it is one of the most important issues on our radar. This is something that can be changed in an instant."
See other media reports here.
For the research, 326 recruited veterinary practices examined 812 cats and 662 dogs using a standardised flea inspection protocol in April and June 2018.
Fleas were collected, the species identified, and pooled flea samples from each host were analysed for the presence of pathogens using PCR and sequence analysis.
Overall, fleas were found on 28.1% of cats and 14.4% of dogs.
Unsurprisingly, over 90% of the fleas on both cats and dogs were our dear old friends, Ctenocephalides felis.
The PCR results found that at least 14% of the samples were positive for at least one pathogen, and 11.3% were positive for Bartonella spp (35 from cats, 4 from dogs), a pathogen which was identified as a risk to veterinary professionals and others with direct animal contact in a 2010 research paper2.
Entomologist Professor Richard Wall from the University of Bristol said: "Fleas are the most clinically important ectoparasites of dogs and cats worldwide.
"Rising levels of pet ownership, climate change and globalisation are increasing the importance of a detailed understanding of the endemicity and prevalence of flea-borne pathogens. This requires continued surveillance to detect change.
"The results have shown the high numbers of cats and dogs that still carry fleas and the relatively high prevalence of Bartonella spp found in the samples provided, which is of significant concern for the health of the pet, pet owner and veterinary practice staff."
Nicola Barclay, Senior Product Manager at MSD Animal Health said: "The Big Flea Project results demonstrate the ongoing need for pet owners to understand the importance of flea prevention, particularly with the implications of infestation for human and animal health.
"It’s particularly important at this time of the year as the weather is getting warmer and infestation is more likely to occur.
"Our national launch today has been designed to raise awareness amongst pet owners and encourage them to seek advice from the veterinary practice.
"Building awareness of the risks of fleas to practices and pet owners is also at the forefront of our ongoing campaign."
References
The service will be available to veterinary practices that use more than £250/€300 of Royal Canin urinary diets per year.
The company has enlisted the support of an independent laboratory to carry out an infrared spectroscopy analysis of the stones, in order to make a quantitative and qualitative assessment of their composition. Royal Canin says that by appreciating the mineral-type in all layers, the best dietary recommendation can be made.
Lee Danks, Royal Canin’s Veterinary Scientific Support Manager, said: "Managing cat and dog urolithiasis can be challenging. This valuable service will improve practices’ diagnostic capacity, enabling a better understanding of a patient’s condition and a much more individualised approach to treatment and long-term prevention."
Royal Canin says there are many complex and interacting contributors to urinary stone formation1. Dietary modifications can influence urine pH, the concentration of minerals within the urine and most critically, urine turn-over through the bladder2. The many interactions between promotors and inhibitors of urolithiasis highlight just how critical a tailored nutritional approach can be to the long-term health of urinary patients.
The figures highlight the burden placed on veterinary surgeons every day when they're asked to euthanise perfectly healthy animals.
Problem behaviours include persistent barking and howling, destructive chewing and inappropriate toileting. Aggressive behaviour, towards both people and other pets, is also a problem, with the PDSA Animal Wellbeing (PAW) report revealing that a third of pet owners have been attacked or bitten by a dog. Such behaviours can cause a breakdown of the human-animal bond, leading to pets being excluded from family life to the detriment of their welfare, relinquished to rehoming centres or euthanised.
The BVA says these figures overwhelmingly show the importance of adequate socialisation of animals at an early age – young animals should safely encounter a variety of people, animals and everyday household sights and sounds in their first few weeks and months of age, beginning at the place where they are born.
Other reasons that owners give their veterinary surgeon for wanting to euthanise a healthy pet included: poor health of the owner (48%), owners moving to accommodation that is unsuitable for their pet (39%), and legal enforcement reasons (32%).
British Veterinary Association President Sean Wensley said: "These figures are stark and are likely to come as a shock to members of the public. But this is the sad reality of a failure to socialise animals from the earliest possible age – a specific time in a puppy’s development which has a significant impact on their future temperament and behaviour. With dogs, this process starts from before a puppy is even seen by a potential owner. In recent months there has been a litany of news stories about the illegal importation, breeding and trading of puppies through puppy farms. This is no way for a family pet to start life and we urge potential owners to thoroughly research where a puppy has been born and reared, using the AWF/RSPCA Puppy contract to help. Then, in the first year of ownership, and especially in the first few weeks, work with your local veterinary practice to ensure your puppy is introduced to everyday sights and sounds, including other people and animals, in a safe and structured way."
Mr Wensley also commented on the impact on vets: "Nobody enters the veterinary profession wanting to euthanise healthy pets, but this is the stressful situation that many vets are facing because of undesirable behaviours in pet animals. Vets will do all they can in these situations to avoid euthanasia, including offering evidence-based behavioural advice, referring to accredited pet behaviourists or assisting with rehoming through reputable rehoming organisations, but sometimes these options are not appropriate, particularly where the behavioural issues make it extremely difficult to rehome the animal. Vets are not required to euthanise healthy animals at an owner’s request, but sometimes, having carefully considered all options and given the circumstances the pet finds themselves in, it may be in an animal’s best interests to do so. Euthanising an animal who could have been a loving pet is the hidden, tragic cost of poor socialisation."
The article points towards the corporatisation of the profession, with 51% of practices now owned by private equity groups and 67% belonging to a group of three practices or more, as the main driver for an increase in vets' fees of over twice the rate of inflation between 2015 and 2020.
However, what the article focuses on, which is the issue of complex and very expensive treatments for pets, is a multifactorial problem which cannot be entirely blamed on corporatisation.
At its heart lie advances in science which now allow vets to offer ever more complex treatments and diagnostics which, when used in human medicine to prolong a human life might sometimes seem expensive, but when used to prolong the life of a dog, can occasionally seem a bit bonkers.
Indeed the article does point towards over-treatment being partly driven by 'celebrity vets advocating increasingly complex surgeries'.
Then there's the fact that both parties to the transaction are often heavily invested in the idea of doing whatever can be done to save the dog: the pet owner, who has anthropomorphised their pet since they first collected it, and the vet, who's entire career has been dedicated to doing their best for the patient in their care.
Then of course there's the inflationary effect of insurance on treatment.
After all, if the animal is insured, why wouldn't you throw the kitchen sink at it?
Things are complicated by the difficulty in estimating the cost of veterinary treatment at the outset, when so much depends on the unknown outcome of diagnostic tests, the progression of disease and the success or failure of treatment. It's not like quoting for a new exhaust system.
There's also the inflationary effect of the increasingly litigious and socially litigious world we live in. It would be no surprise if veterinary surgeons have become more likely to test for everything, when the consequences of missing something is a soul-destroying trial by social media.
And finally, there's the subjective value of money.
Nevertheless, the Daily Mail has a point.
Selling any product or service is about meeting clients' and customers' needs.
If you keep increasing the price of your product range until all you can offer is a Rolls Royce, sooner or later you're going to price yourself out of the market.
One other lesson for the profession from that article: 'No comment' is not a good look for a caring profession.
Zoetis has launched UlcerGold (omeprazole) for the treatment - and prevention of recurrence - of gastric ulcers in horses and foals, presented in a syringe suitable for foals from four weeks of age and horses from 70 to 700kg.
Equine Gastric Ulceration Syndrome (EGUS) is a serious and common condition affecting horses and foals.2,3 Approximately 90% of racehorses, 60% of performance horses, 37% of leisure horses and 50% of foals have been shown to be affected.2,4,5 The condition is associated with injury to the mucosa of the oesophagus, stomach and duodenum, with prolonged exposure to gastric acid thought to be the primary cause.2,3 Risk factors include stress, intense exercise, a high-grain diet, intermittent feeding and illness.2,3 EGUS can have a profound impact on a horse's condition and performance and can ultimately be life threatening, especially in foals.3,5 It is a challenging condition to diagnose as the clinical signs are often vague and not always present.3 Gastroscopy is the only method currently available for a definitive diagnosis and treatment is usually based on acid suppressive therapy to allow ulcer healing.2
UlcerGold is indicated to treat and prevent the recurrence of gastric ulcers in horses, administered once-daily for 28 consecutive days at the full dose of 4mg/kg bodyweight followed by the reduced dose of 1mg/kg bodyweight for a further 28 days.1 It contains omeprazole, a proton pump inhibitor that suppresses gastric acid secretion.1,2 One syringe contains enough UlcerGold for a horse weighing up to 700kg. It can be used for foals as young as four weeks of age that weigh over 70kg and for breeding stallions.
Zoetis says UlcerGold is supported by a comprehensive gastroscope training programme, pricing model, client support and communications plan to ensure that it is a strong asset to veterinary businesses.
Penny McCann, Equine Product Manager, Zoetis UK Ltd, said: "UlcerGold is an exciting addition to our equine POM-V portfolio. We have designed a training, education and business programme to help practices make sure they get the best from our new product, not only in terms of gastric ulceration treatment but also practice health."
The RCVS Disciplinary Committee has agreed to adjourn multiple charges against an Essex-based veterinary surgeon who qualified in 1969, following his undertakings firstly to request removal from the RCVS Register and secondly never apply to be restored to it.
At the hearing, which had originally been listed for seven days, Geoffrey Raymond Oliver, 68, was charged with serious professional misconduct over allegations of his inadequate treatment of two dogs and a cat (belonging to three different clients) between 2010 and 2012; inadequate record keeping; failures to deal honestly or properly with his clients; and, failure to heed advice from the RCVS Preliminary Investigation Committee about the importance of proper communication between veterinary surgeons and their clients.
However, before the Committee heard evidence on any aspect of these charges, Mr Oliver lodged his application for adjournment. The Committee therefore made no findings on the charges, and emphasised they had neither been proved against, nor admitted by, him.
The Committee noted that there had been no adverse findings against Mr Oliver during his professional career, that his practice was now closed and that he had no intention of returning to practise in the future. Should he subsequently apply to be restored to the Register, the Committee would resume its consideration of the charges, along with his breach of the undertaking.
The Committee was advised that none of the complainants in the case - which could have incurred considerable time and costs - dissented from the proposed course of action.
Speaking on behalf of the Disciplinary Committee, its Chairman, Professor Peter Lees, said: "The Committee has concluded that no useful purpose would be served were it to insist on a full hearing [and it] would be a disproportionate waste of...resources [to do so]. The Committee is satisfied that [granting the adjournment application] protects the welfare of animals and...is in the public interest."
The Committee then accepted Mr Oliver's undertakings, including the removal of his name from the Register with immediate effect.
Professor Lees added: "So that he is in no doubt about the matter, the Committee reminds [Mr Oliver] that, when referring clients of his former practice elsewhere, he should be careful to avoid giving them any advice about the diagnosis or treatment of their animals."
BVA President Sean Wensley said: "The UK's decision to leave the European Union will have a significant impact on matters of interest to the veterinary profession, particularly in relation to regulation, education, and workforce planning, but also in terms of animal welfare, research, surveillance, and animal movements.
"BVA will work hard to ensure the voice of the veterinary profession is heard during the negotiation and discussions that will now begin, in order to secure the best possible outcomes for our profession and for animal health and welfare in the UK. The Vet Futures report provides an excellent summary of issues we need to consider in those discussions, and the Vet Futures Action Plan, due to be launched at the Vet Futures Summit on 4 July, outlines key initiatives that we need to take forward, albeit with revised timelines while the full impact of Brexit is determined.
"BVA will retain an outward looking and inclusive perspective through our relationships with international partners, including the Federation of Veterinarians for Europe (FVE), Commonwealth Veterinary Association (CVA) and World Veterinary Association (WVA) to ensure the UK veterinary profession continues to influence and engage on cross border issues such as disease surveillance, veterinary medicines and antimicrobial resistance."
Lead author Professor Clare Rusbridge, Chief of Neurology at Fitzpartick Referrals, conducted the study because of a lack of clarity on the recognition and diagnosis of the clinical signs associated with CM as opposed to syringomyelia (SM).
CM is an abnormality in the skull, making it smaller, and impacting on the brain to alter the flow of cerebrospinal fluid; this results in pain and a collection of fluid pockets within the spinal cord. These fluid pockets are commonly known as SM and over time can cause irreversible damage to a dog’s spinal cord. However it is not clear whether signs of pain in affected dogs are due to CM or SM or both.
To try to rectify this, Clare studied the medical records of all the cavalier King Charles spaniels diagnosed with CM-associated clinical signs presenting to her at Fitzpatrick Referrals over a five year period. She documented the historical and examination findings and related them to the MRI findings, including presence and size of the SM.
She found common signs in all dogs were vocalisation, spinal pain (neck, middle or lower back), reduced activity, reduced stairs or jumping ability, aversion to being touched or groomed, altered emotional state (described as being more timid, anxious, withdrawn or aggressive) and sleep disturbance.
A tendency to rub or scratch at the head or ears was common but was more likely in dogs with small or no SM suggesting that this may be a sign of head discomfort associated with CM. Head and ear rubbing was not associated with the presence of material within the middle ear (a condition which is also common in this breed and often given the acronym PSOM).
The only signs that were specific to SM were phantom scratching, scoliosis (twisted spine) and weakness and these were only present when the SM was large (at least 4mm wide).
Clare says this study is important because it suggests that CM alone is a cause of pain in many dogs. The aim now is to use the information gained in this study to develop a questionnaire to determine risk of CM and monitor the response to clinical signs.
Photo: Charlie on a bad day
The company’s NEMO Cardiac Health Screening test detects heart disease using AI to analyse microRNAs - biomarkers that manage the immune system and its responses and act as regulators for disease progression or resolution.
MI:RNA says the new test, which can be taken from blood or urine samples, will help vets diagnose and monitor disease progression more effectively and give cats and dogs with heart disease 18 months more life.
Eve Hanks, CEO and founder of MI:RNA (pictured) said: “The use of precision medicine in veterinary diagnostics will help pet owners and breeders alike to ascertain where to direct their efforts and finances accordingly.
"There is massive potential to use this technology to help breeds who have real problems with heart and other diseases, and will consequently help owners and breeders to identify affected animals more quickly.
Professor Joanna Dukes-McEwan, Head of the Cardiology Service at the University of Liverpool said: "From our cardiac investigations, we knew exactly the underlying heart disease and the severity of this, so our data was used as a training set for the MI:RNA panel analysis.
"We have previously collected samples from dogs with myxomatous mitral valve disease and are currently collecting samples from cats with hypertrophic cardiomyopathy.
“I think the MI:RNA panels are most useful for vets in primary care practice to identify and confirm the severity of underlying cardiac disease in their patients.
"A simple blood test which could confirm that the cause of a heart murmur is MVD, and also indicate its severity, and whether the patient would benefit from treatment would be really helpful for primary care vets in practice.
"They might indicate which patients may benefit from referral, or indicate when a specific treatment is indicated.
"Future research with miRNA panels may also indicate novel pathways in progression of disease which might increase our understanding of the disease, or novel therapeutic options.”
Miss Padron Vega faced four charges. The first and second alleged that in February 2016, for the purposes of an application to the Food Standards Agency for a Certificate of Competence under the Welfare of Animals at the Time of Killing Regulations 2015, she backdated two separate veterinary witness certificates to 7 December 2015. The third charge alleged that her acts of backdating were misleading, dishonest and in breach of the RCVS Principles of Certification.
The fourth charge against Miss Padron Vega was that, between September 2015 and February 2016, she failed to fulfil her duties as an Official Veterinarian in respect of: failing to prepare herself for the implementation of the Welfare of Animals at the Time of Killing Regulations 2015; failing to have regard to the information provided to her by her employers about the regulations and their implementation; failing to take any steps to ensure that the two individuals for whom she had given veterinary certification were licensed to perform slaughter in accordance with the regulations; and failing to identify that two individuals were not licensed to slaughter in accordance with the regulations.
The Committee heard that the Welfare at the Time of Killing Regulations were introduced on 5 November 2015 which placed the responsibility on slaughtering operations not to permit animal welfare abuses and required certification by a veterinary witness regarding compliance.
The new regulations required existing slaughter licence holders to apply for a Certificate of Competence before midnight on 8 December 2015 or they would not be permitted to continue operating even with experienced operatives.
During the hearing, Ms Padron Vega admitted charges 1 and 2, admitted that she had been in breach of the Principles of Certification and admitted the fourth charge against her.
However, she denied she had backdated the certificates in a misleading or dishonest way, maintaining that she had done so by mistake.
In considering the facts of the case, however, the Committee rejected this argument and, taking into account that she had been responsible for veterinary certifications in the UK since 2001, found that her conduct was knowingly misleading and dishonest.
The Committee then went on to consider whether the charges she admitted and the charges found against her constituted serious professional misconduct, both individually and cumulatively.
The Committee found that all the charges amounted to serious professional misconduct.
In relation to charge 4 in particular Stuart Drummond, chairing the Committee and speaking on its behalf, said: "The Committee has found that the respondent failed to read even those emails which her employer sent to her which were marked ‘urgent’ or ‘OV importance high’. She must have known that her employers were directing attention to some new statutory scheme for she was provided with PowerPoint slides in that regard which she could read at any time of her convenience. The Committee has been driven to the conclusion that the respondent did not even bother to read those slides for, had she done so, she would have known that she needed to apprise herself of the requirements of the impending new statutory scheme.
"The respondent’s failings in this regard are little short of extraordinary, especially given her obligations as Lead OV for FAI Farms. The total abdication of her responsibility to understand the requirements of the Regulations governing the slaughterhouse operations constitutes, in the judgement of this Committee disgraceful conduct in a professional respect."
The Committee then went on to consider the aggravating and mitigating factors in the case. In terms of aggravating features the Committee noted a lack of insight into the gravity of her conduct, that her conduct undermined in the most serious way public confidence in veterinary certification, and that there were animal welfare implications on her conduct as a number of chickens had to be removed from the slaughterhouse and alternative arrangements made because an auditor from the Food Standards Agency found that it was not compliant.
In mitigation the Committee considered that, despite the potential risk of harm, there was no actual harm occasioned to animals, that Miss Padron Vega has had a long and otherwise unblemished career and no previous issues with the RCVS and that she had admitted some of the charges against her.
Stuart Drummond added: "Ultimately, the Committee was driven to the conclusion that the public’s desire to see the implementation of the highest certification standards in relation to activities which impact on animal welfare and public health, and which did not occur on 3 February 2016, must outweigh this particular veterinary surgeon’s desire and need to continue in practice. This is not a conclusion which the Committee has arrived at lightly. On the contrary, it has reached this decision because it has been driven to the conclusion that it would be failing in its public duty to protect the wider public interest in the maintenance of standards of honesty and right conduct in a member of the profession.
"It is, therefore, the conclusion and decision of this Committee that the only proper sanction that can be imposed in this case is that the respondent’s name should be removed from the Register and it directs the Registrar accordingly."
Miss Padron Vega has 28 days from being informed of the Committee’s decision to lodge an appeal with the Privy Council.
The independent practice, which was set up in 2010 by husband and wife team Richard and Sophie Aylett, will be a hard act to follow because not only did they achieve awards in all three areas for which they were eligible, but they were marked as "Outstanding" in all three.
For farm practices, the five possible awards are: Team and Professional Responsibility, Client Service, Advisory/Consultancy Service, Diagnostic Service and In-Patient Service. However, as an ambulatory first opinion farm animal practice, Meadows Farm Vets Ltd was only eligible for the first three awards.
Comments from the PSS Assessor included:
"Clinical governance was developing well in the practice. The recording of all surgeries in a file but also in an easy to see chart on the wall, colour coded re follow up was an excellent idea."
"Infection control & biosecurity were taken very seriously and all vehicles were immaculately clean & tidy."
"There was great support provided to new graduates and a comprehensive induction for new team members."
"The resources for farmers including written reports, training meetings, general meetings and comprehensive monthly newsletters were the best I have seen in a farm practice."
"The use and monitoring of a surgical checklist for all surgical procedures was impressive."
Practice Principal Sophie Aylett said: "We are extremely proud to have been recognised by the Royal College for our modern and innovative approach to farm practice. It has been a real team effort in working towards these Awards and we are very excited to be the first farm animal practice to have achieved all three Awards.
"To be marked as “Outstanding” in all three areas is testament to the great team of competent, confident and content vets and staff who are Meadows Farm Vets Ltd."
Bovilis Nasalgen-C can be used for the active immunisation of calves from the day of birth onwards to reduce clinical signs of upper respiratory tract disease and nasal viral shedding from infection with BCoV.
MSD says respiratory disease in UK calves is widespread and comes at a high cost from an emotional and business productivity perspective.
It is also continually highlighted as a critical area for overuse of antibiotics.
Despite all this, there is an under use of vaccination in the UK cattle sector1.
Speaking at BCVA last week, Paul Burr MRCVS, director of Biobest Laboratories said: “Recent UK studies show bovine coronavirus being the most prevalent virus found in routine disease screening and nasal swab samples taken during a bovine respiratory disease outbreak.
"BCoV was found in 39% of over 400 nasal swab samples taken between 2020 and 2022 from BRD affected cattle on UK farms2.”
Kat Baxter-Smith, veterinary adviser with MSD Animal Health, said: “Whilst the pathogenicity of BCoV within the BRD complex remains an unknown quantity, its ubiquitous presence in the UK cattle population – and the recent human experience of coronavirus as a significant respiratory pathogen – suggests a need for a re-evaluation of BRD control by vets and farmers.
“Just as coronavirus is a pathogen associated with the common cold and Covid-19, BCoV is a proven pathogen that directly impacts the calf respiratory tract.
"Consequently, the availability of this new BRD vaccine presents veterinary professionals with another tool in their armoury to improve control of this costly disease.
“If diagnostics suggest BCoV is implicated in any BRD problem, the availability of Bovilis Nasalgen-C allows UK cattle farmers to effectively administer protection for young calves via a single 2ml intranasal dose that can quickly reach the site of action.
"This will support the development of immunity against BCoV early in life, the onset of which starts five days after administration and has a 12-week duration.”
Bovilis Nasalgen-C comes can be used on the same day with Bovilis INtranasal RSPÔ Live, which offers protection against both Bovine Respiratory Syncytial Virus (BRSV) and Parainfluenza-3 Virus (Pi3).
Bovilis Nasalgen-C can be stored for up to 24 hours at room temperature after reconstitution, can be given to cattle using a syringe or applicator device and is available in one, five and 20 dose packs, suitable for both small and large herds.
References:
Fitzpatrick says that the initial results from a study at the University of California Davis has shown a reduction of up to 40% in the volume of prostatic tumours following embolisation, along with significant improvements in the patient's quality of life (the ability to pass urine and faeces in particular)1. However, prostatic embolisation in veterinary patients has only been performed in a small numbers of centres globally and not previously in Europe.
Gerard McLauchlan (European and RCVS Specialist in Small Animal Internal Medicine, Fitzpatrick Referrals Oncology and Soft Tissue) first carried out the procedure in December 2018 and has since performed it on two more patients.
Fitzpatrick is now offering prostatic embolisation alongside targeted intra-arterial (IA) chemotherapy, a treatment which it has now given to over forty patients with urinary tract tumours in the past 24 months, leading to a reduction in tumour size of up to 30% and an improvement in clinical signs.
Gerard said: "We have been developing and refining new techniques for treating various cancers over the past two years at our oncology and soft tissue centre. Really excellent results have been seen so far in cases with prostate cancer treated with intra-arterial chemotherapy and embolisation is the next logical step for managing this condition.
"Prostatic embolisation has only been performed at two centres in the United States and has shown very promising results in terms of patients quality of life and overall survival.
"With a recent study documenting the mean survival of patient with prostate cancer receiving standard intravenous chemotherapy as being only 101 days these new techniques offer an amazing opportunity to truly change how we view and manage this condition."
The Society of Practising Veterinary Surgeons (SPVS) has published its 2014 Salaries Survey which showed that the gender pay gap has closed from 15% last year to 10.8% this.
However, the association notes that this is still slightly higher than the gap reported for all professions in the UK, so there remains work to be done.
The survey, which is the largest of its kind and drew responses from 1,878 vets, nurses, practice managers and receptionists also found that:
Peter Brown, SPVS Treasurer and author of the report comments: "The SPVS Salaries Survey is intended as a benchmark to give some indication of what is being paid as the 'going rate' rather than to advise on what employees should be paid. Having said that, we would urge all veterinary practices to continue working to ensure that equal rates of pay are given for positions of equal status. Although the gender gap has closed up, it is still too big."
The annual SPVS Salaries Survey is free of charge to SPVS members and costs £150 for non-members. For more information, call 01926 410454 or visit www.spvs.org.uk.
Pfizer Animal Health has launched Zylexis for horses, the first and only immunomodulator licensed in the UK to reduce the clinical signs of equine respiratory disease associated with over-crowding and stress.
Zylexis contains inactivated parapox ovis virus (iPPOV), a super-antigen which Pfizer says boosts a horse's immune system to reduce the effects of infectious respiratory disease1,2 - bridging the gap between potential and performance.
According to the company, Zylexis acts by stimulating the horse's non-specific immune system, inducing antiviral interferons and interleukins and stimulating innate immune cells. In this way it bridges the gap until the horse's adaptive immune system can develop a pathogen-specific response.3-5
Pfizer highlights research which has shown a 40.3% reduction in the clinical signs and duration of respiratory disease in young horses under conditions of crowding and stress and a significant reduction of purulent nasal discharge when using Zylexis.6,7 No local or systemic adverse events were observed in a 999 dose study.8
Wendy Talbot, National Veterinary Manager at Pfizer, said: "Zylexis has been licensed in the States and in Germany for a number of years. We believe Zylexis plays a pivotal role in helping to minimise the severity of respiratory disease outbreaks in these countries, therefore helping to maintain performance potential. It's a very welcome addition to the medicine box of UK vets."
The administration of Zylexis is recommended as a course of three single dose intramuscular injections on days 0, 2 and 9. The first dose should be administered shortly before the over-crowding or stressful situation.
Research shows that over 60% of cast-treated pets get additional injures, such as pressure sores, from traditional plaster casts1.
The new cast is designed to tackle these issues with anatomically shaped bi-valve splints that are based on 30,000 3D scans of animal limbs.
Upets TLC products are made from FDA and CE approved Woodcast material used in human casting and splinting.
Bandages, padding and tape are replaced with a soft, self-cohesive Unitex fabric that passes moisture and dries fast.
TLC products are engineered for easy destabilisation by removing parts of the splint, and the same product can be used throughout the whole treatment.
Orthopets, a subsidiary of the materials company Dassiet, says that breathable, lightweight materials combined with the anatomical fit help prevent sores and restore normal position and movement of the limb.
OrthoPets founder Martin Kaufmann said: “The common cast is very problematic, but we've lacked better alternatives. Now, with the Dassiet supermaterials and OrthoPets’ vast experience in veterinary biomechanics we have re-engineered the common cast.
"Upets TLC is anatomical and safe. It’s stress-free for both the vet and the pet. It brings veterinary casting to the modern day and offers a better standard care option for all vets and orthopaedic surgeons out there.”
"Sores, pain and stiffness are always on the horizon with casting. But if we take the cast off too early, the leg can be injured again because of lack of proper support. UPETS tackles these problems all at once. I find it easy to apply the pre-shaped casts even for very small or large dogs and make adjustments if needed. I can watch my patients walk off the clinic normally with their cast, knowing they can wear it safely until fully healed. We see significant and immediate improvement in patients compared to the common cast”, says Dassiet Chief Veterinarian Jouni Niemi, who oversees the clinical research of UPETS.
For more information, visit: www.upets.vet/TLC
Remote consultations and prescribing have been the subject of much debate in the profession of late. A motion to conduct a trial of prescribing without a physical examination was considered by the RCVS Council in November, when a large number of serious concerns were raised.
However, none of those concerns related to the provision of remote consulting services for existing clients with animals who are already under the care of the veterinary surgeon. That's where systems like this could add real value to the service offered by veterinary practices.
George Kyriacou, Director at VVG said: "Telemedicine is happening, and it’s happening in a big way. Virtual consultations are becoming more and more popular with pet owners who are not really sure if they need to see a vet and would simply like some reassurance.
"An option to have a qualified vet in your pocket at anytime of the day is attractive. However, the option to have a convenient consultation with your own trusted vet is the holy grail."
The system allows those practices who wish to charge for online consults to take payment online. Some, however, offer free consultations, in particular post-op, because it saves everyone time.
VVG points out that the system can also be used to deliver nursing consultations, too.
Simon Power, Commercial Manager at Vets One referrals in Crimplesham, Norfolk said: "Since adopting the system we have had a number of post-op and medication reviews virtually; it not only saves us a consulting room but also allows our clients to have the expert advice our team provide from the comfort of their own home."
VVG costs £249 to set up, plus from £59 per month thereafter, per practice.
For more information, contact George Kyriacou at George@thevvg.com or call 01842558022.
EthyCalm is sprayed directly on the skin, or, for more fractious patients, can be applied with a swab.
Invicta says that unlike other products the effect is instant and EthyCalm leaves no residue on the skin surface.
The improved product, EthyCalm Plus, contains 50% more product (good for over 100 applications) and incorporates a new 'on-off' switch for easier application. It is also now packed in a 'no-roll' case to protect from damage.
Rob Watkins, Managing Director of Invicta, said: "EthyCalm has been an incredibly popular product with nurses and vets. As a small company we always listen to our customers and have taken the opportunity to incorporate suggestions for improvement. The result is EthyCalm Plus which offers significant enhancement over the original product".
EthyCalm Plus is available from veterinary wholesalers and for a limited time the price has been held at £25 each.
Outcome of temporary tracheostomy tube-placement following surgery for brachycephalic obstructive airway syndrome in 42 dogs1 was undertaken at Dick White Referrals, UK. A retrospective case series of dogs that had a temporary tracheostomy tube placed in the post-operative period following surgery for BOAS was obtained from the referral hospital.
Of the 42 dogs, 11 had a tracheotomy tube placed electively and 31 had one placed as an emergency. The overall postoperative complication rate in the study was 95%. The minor complication rate – defined as resulting in no observable compromise of the clinical status and/or self-limiting, such as a cough - was 71%. The major complication rate – defined as resulting in discernible harm to the patient, such as cyanosis and dyspnoea - was 83%. 41/42 dogs were classified as having successful tracheostomy tube management.
Marius Stordalen, lead author of the paper said: "Contrary to what had been previously thought, this manuscript shows that in an appropriate clinical setting, temporary tracheostomy tube placement following multi-level airway surgery for brachycephalic obstructive airway syndrome carries a good prognosis for the majority of patients."
Nick Jeffery, editor of JSAP added: "Whilst overall mortality rate was low following placement of a tracheostomy tube in the postoperative period, there was a high overall complication rate. This finding demonstrates the need for continuous monitoring and intensive care for patients following placement of tracheostomy tube.”
The full article can be found in the May issue of the Journal of Small Animal Practice which is free for BSAVA members. It can also be read online here: https://onlinelibrary.wiley.com/doi/10.1111/jsap.13127
The study, titled ‘Physics of animal health: On the mechanobiology of hoof growth and form’, represents the fruit of a collaboration between researchers in equine medicine, maths, physics and stem cell biology. It was conducted by the School of Veterinary Medicine and Science at University of Nottingham in collaboration with the Waltham Centre for Pet Nutrition and the Royal Veterinary College.
Lead author Dr Cyril Rauch said: "With new scientific inputs from physics, mathematics and biology, this study provides an entirely new paradigm regarding hard growing tissues such as the horse hoof, which can be applied across cattle, sheep and other species, to unify a set of apparently disparate conditions and clarify the roles of physics and/or biology."
Using hooves from horses euthanased for non-research purposes, the study revealed how it is possible for the hoof growth rate to be greater than the potential proliferation rate of epithelial cells. It also explained how the synthesis of the hoof capsule starts from the coronet and that the soft papillae undergo gradual transition through three interpapillary regions into hard keratinised tissue.
Mathematics, physics and cell biology were then used in the study to explain and describe how the dorsal hoof wall can grow in a curved manner rather than the usual straight manner as a result of faster growth from the coronary band at the quarters compared to the toe region.
Evaluation of the feet from live underweight and obese subjects (assessed using Body Condition Scoring) allowed the influence of body weight on the balances of the stresses affecting hoof growth to be evaluated. The results suggest that being proportionally heavier may promote straighter hoof growth and that being too lean may precipitate poor hoof growth and the development of a hoof with a dorsal curved shape.
The study also showed that a high concentration of insulin stimulated equine progenitor keratinocytes (the outermost layer of cells on the hoof wall) to grow in culture. If this also happens chronically within the live animal, it is possible that it could affect the growth stresses within the hoof and so promote a dorsal curved hoof shape.
Co-author Nicola Menzies-Gow said: "These results taken together can explain how the hoof grows and how it is possible for it to develop a dorsal curvature. However, it should be acknowledged that this does not take into account the genetic or metabolic influences on hoof growth nor the role of hoof trimming and shoeing in maintaining a mechanically healthy hoof. It is appreciated that the underlying biology of hoof growth remains an essential factor for hoof pathologies."
Dr Cyril Rauch continued: “Given that the hoof is a weight bearing element it is essential to untangle the biology from the physics in this system; only then can meaningful biological and/or physical causes be prescribed for particular hoof shape. Removing the cause(s) when physically or biologically possible is essential to resolve hoof conditions."
The company says that the effervescent tablet presentation was designed to significantly improve vaccination practices for poultry producers while maintaining reliable virus protection.
Boehringer says this dispensing form reduces the risk of stock solution contamination and, when compared to glass vials, the small blister packs make vaccine management safer for operators, take up less room in the fridge and reduce packaging waste by 90%.
HatchPak IB H120 NeO will be available shortly in packs of 10 tablets of 1000 doses or 10 tablets of 2000 doses.
Callum Blair, Boehringer Ingelheim Avian and Swine Brand Manager, said: "The addition of HatchPak IB H120 NeO to our NeO product portfolio is evidence of our continued investment in the poultry sector."
The authors say that study seeks to redress the lack of evidence-based information that has so far been published on the epidemiology and clinical management of non-neoplastic anal sac disorders (ASD).
The study, which was carried out within the RVC’s VetCompass programme, focused especially on identifying breeds with increased or reduced risk of anal sac disorders.
The breeds at greatest risk of an anal sac disorder compared with crossbreeds included Cavalier King Charles spaniel, King Charles spaniel and Cockapoo.
Conversely, breeds at reduced risk included larger breed dogs including Boxer, German Shepherd Dog and Lurcher. Flat-faced (brachycephalic) breeds such as Shih Tzu had 2.6 times the risk for anal sac disorders compared to long-skulled breeds such as Border Collies. Spaniel-types, Dachshund-types and Poodle also showed increased risk for anal sac disease.
The study identified 2,372 anal sac disorder cases from a population of 104,212 dogs attending VetCompass participating practices during 2013.
Other findings included:
Dr Dan O’Neill, Senior Lecturer, Companion Animal Epidemiology, at the RVC, and author of the paper, said: “During two decades in first opinion practice, anal sac problems in dogs were a routine daily presentation for me. However, when I searched the literature to find evidence on the best way to treat these dogs or even on which breeds were at most risk, there was almost no information available. It seemed back then that only problems that were severe enough to be referred to universities in large numbers were researched.
"As a result, vets in first opinion practice generally had to work out for themselves what seemed to be the best treatment in these cases. It is refreshing now to see research on common problems in dogs under first opinion veterinary care being reported. Owners and vets needs this evidence vitally.”
Anette Loeffler, Associate Professor of Veterinary Dermatology at the RVC and co-author of the paper, said: "This study shines a spotlight on critically important area of veterinary practice: antibiotic usage. Twenty percent of dogs presenting with an anal sac disorder received antibiotics even though diagnostic criteria for anal sac infection or proof of efficacy of antibiotic treatment are lacking.
"At a time when antimicrobial resistance presents one of the biggest threats to human and animal health, this highlights an urgent need for further study of these disorders in order to improve dog welfare but also to help vets in making responsible antibiotic treatment decisions in the interest of public health.”
Animals Count, which describes itself as a political party for people and animals, will launch its EU election manifesto on 24th May from 12 noon at the Kings Oak, Loughton, where it will be putting into practice one of its proposed policies: subsidised basic and emergency animal health care for animals. Animals Count President and veterinarian, Andrew Knight, will provide free dog consultations and animal health care advice for all companion animals.
Animals Count will contest the European Parliament elections, taking place on the 4th of June. It hopes to end farming with poor welfare consequences for animals, long distance live animal transport, all hunting for sport, and introduce an EU-wide subsidised basic animal health care system.
Animals Count Leader, Jasmijn de Boo MSc., said: "Concern for animals has long been a mainstream priority, yet remains poorly represented by most political parties. In several countries political parties for animals have formed to meet this need. The Dutch Party for the Animals from which we grew now has 20 elected representatives, including 2 MPs and one senator."
"The EU elections are particularly important for people and animals. Around half the EC budget is spent on agriculture. Given today's economic climate there's never been a better time to re-examine the massive expenditure of tax-payer money on farming methods known to be strongly associated with poor animal welfare and serious environmental damage."
Miss de Boo, 33, Alex Bourke, 47, Vice-chair of Animals Count and best-selling author of the 'Vegetarian Guides' book series, and Richard Deboo, 41, City professional and public speaker on animal issues, will contest the June EU elections in the Eastern region of the UK. Animals Count's ultimate goal is a world in which animals are not exploited, and are treated as sentient beings.